Stanley Gibbons
SGI
$63.36
-2.58%
Somnigroup International Inc. is a vertically integrated bedding company that designs, manufactures, distributes, and retails sleep products — including mattresses, adjustable bases, pillows, and related accessories — under owned brands such as Tempur-Pedic, Sealy, and Stearns & Foster, and operates retail banners including Mattress Firm and Tempur Sealy North America across more than 100 countries. The company occupies a dominant position in the global bedding industry as the largest manufacturer and one of the largest specialty retailers of sleep products, giving it a rare combination of wholesale brand power and direct-to-consumer distribution control. The current investor narrative centers on the integration and synergy realization from the transformational Mattress Firm acquisition, which dramatically expanded the retail footprint and revenue base but also loaded the balance sheet with debt and compressed near-term profitability. Recent attention has focused on whether the company can convert its omnichannel scale into durable margin expansion and free cash flow generation, with the latest quarterly results showing a return to profitability and double-digit revenue growth, while the stock's sharp year-to-date decline reflects lingering skepticism about consumer discretionary demand and leverage. Management's decision to maintain and grow its dividend signals confidence in cash flow durability, but the debate remains whether the retail-heavy model can sustain premium multiples in a soft housing and big-ticket consumer environment.…
SGI
Stanley Gibbons
$63.36
Related headlines
Investment Opinion: Should I buy SGI Today?
We assign a Hold rating on SGI, balancing the strong sell-side consensus (strong buy, $91.89 average target) against the company's leveraged balance sheet and uncertain margin trajectory. The core thesis is that the market is overly pessimistic on the Mattress Firm integration, but the risks are too high to justify a Buy until there is clearer evidence of sustainable deleveraging and margin expansion. The 37.6% upside to the average target is compelling, but the 9.5% downside to the 52-week low and the potential for further multiple compression warrant caution.
The supporting evidence is mixed but leans positive: revenue grew 12.26% year-over-year in Q1 2026, net income swung to $104.2 million from a loss, and free cash flow of $736.8 million provides a 4.0% yield. The forward PE of 16.92x is below the sector average, and the PS ratio of 2.46x is near historical lows. However, the EV/EBITDA of 25.49x is elevated, and the debt-to-equity of 2.66x remains a concern. Analyst estimates for $6.30 EPS imply a significant earnings recovery, which if achieved would justify a much higher stock price.
The biggest risks that could invalidate the thesis are: 1) a consumer recession that depresses big-ticket spending, 2) failure to realize Mattress Firm synergies, leading to margin stagnation, and 3) a liquidity crunch if cash flow deteriorates. We would upgrade to Buy if the company demonstrates two consecutive quarters of margin expansion and debt reduction, or if the forward PE compresses below 15x. We would downgrade to Sell if revenue growth turns negative or if the current ratio falls below 0.7. Relative to its own history and peers, SGI appears undervalued on a sales basis but fairly valued on an EV/EBITDA basis, suggesting the stock is pricing in a successful turnaround that has yet to fully materialize.
Sign up to view all
SGI 12-Month Price Forecast
SGI presents a balanced risk/reward profile, with the potential for significant upside if integration synergies materialize, but substantial downside if consumer demand weakens or margin recovery stalls. The stock's 24.77% YTD decline and 16.8% positioning within its 52-week range suggest that much of the pessimism is priced in, yet the leveraged balance sheet limits flexibility. We would upgrade to bullish if the company reports two consecutive quarters of margin expansion and debt reduction, and downgrade to bearish if revenue growth turns negative or liquidity deteriorates further.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stanley Gibbons's 12-month outlook, with a consensus price target around $93.44 and implied upside of +47.5% versus the current price.
Average Target
$93.44
0 analysts
Implied Upside
+47.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $105
Analyst target range
Nine analysts cover Somnigroup with a consensus recommendation of "strong buy" and a recommendation mean of 1.4 (where 1.0 is a strong buy and 5.0 is a sell). The average price target of $91.89 implies 37.6% upside from the current price of $66.76, a substantial gap that reflects analyst confidence in the company's earnings recovery trajectory. The consensus leans decisively bullish, with the strong buy rating and the magnitude of the target premium suggesting that sell-side analysts view the recent sell-off as an overreaction to integration and leverage concerns rather than a reflection of deteriorating fundamentals.
The target range spans from a low of $66.00 to a high of $105.00, a spread of $39.00 or 59% of the low target, which signals meaningful disagreement about the company's trajectory. The low target of $66.00 is essentially at the current price, implying that the most bearish analyst sees no upside and prices in persistent margin compression, consumer weakness, and leverage constraints. The high target of $105.00 assumes successful synergy realization, multiple expansion toward historical norms, and accelerating earnings growth that validates the $6.30 forward EPS estimate. The institutional ratings history shows a constructive tilt: Jefferies upgraded from Hold to Buy on March 26, 2026, and UBS, B of A Securities, and Truist have maintained Buy ratings through 2026, with no downgrades in the visible data. The wide target spread, combined with the strong buy consensus, suggests that while analysts are collectively bullish, the market is not yet convinced — creating potential for significant re-rating if upcoming quarters demonstrate tangible progress on margins and deleveraging.
Drowning in data?
Find the real signal!
Bulls vs Bears: SGI Investment Factors
The bear case currently has stronger near-term evidence, given the stock's 24.77% YTD decline, elevated leverage (D/E 2.66x), and sequential margin compression, but the bull case is gaining traction with a 12.26% revenue growth and a return to profitability. The most important tension is whether the forward EPS estimate of $6.30 is achievable; if it is, the forward PE of 16.92x is attractive and the stock could re-rate toward the $91.89 average target, but if margin recovery stalls, the trailing PE of 48x remains vulnerable. Analyst sentiment is overwhelmingly bullish (strong buy, 1.4 mean), yet the market is skeptical, creating a potential inflection point if upcoming quarters show tangible deleveraging and margin expansion. The wide target range ($66–$105) underscores the binary nature of the investment debate, hinging on integration execution and consumer demand.
Bullish
- Strong Buy Consensus with 37.6% Upside: Nine analysts rate SGI a 'strong buy' with a mean recommendation of 1.4 and an average price target of $91.89, implying 37.6% upside from the current $66.76. The high target of $105.00 suggests that some analysts see even greater recovery potential, and the absence of any downgrades in the visible ratings history (Jefferies upgraded to Buy in March 2026) reinforces the constructive sell-side view.
- Revenue Growth and Margin Recovery: Q1 2026 revenue grew 12.26% year-over-year to $1.802 billion, and net income swung to $104.2 million from a loss of -$33.1 million in Q1 2025. Gross margin recovered to 43.61% from 36.17% a year ago, and operating margin reached 11.52%, demonstrating successful integration of Mattress Firm and improving profitability.
- Attractive Forward Valuation: The forward PE of 16.92x is well below the trailing PE of 48x and below the broader consumer discretionary sector average, based on estimated EPS of $6.30. The PS ratio of 2.46x is near the low end of its historical range (5.84x–10.03x), suggesting the stock is cheap relative to sales if margins normalize.
- Solid Free Cash Flow Generation: Trailing twelve-month free cash flow is $736.8 million, yielding approximately 4.0% on the $18.39 billion market cap. Q1 2026 operating cash flow of $246.5 million comfortably covers $60.5 million capex, $36.7 million dividends, and $141.8 million debt repayment, indicating the business can self-fund its obligations.
Bearish
- Elevated Leverage and Weak Liquidity: Debt-to-equity stands at 2.66x, and the current ratio of 0.83 indicates current liabilities exceed current assets. The cash flow to debt ratio of just 0.038 highlights that deleveraging will take years, leaving the company vulnerable to interest rate or demand shocks.
- Severe Relative Underperformance: SGI is down 22.45% over the past year and 24.77% year-to-date, versus the S&P 500's +16.22% and +12.08% respectively, producing a relative strength of -38.67 over 12 months. The stock trades at just 16.8% of its 52-week range, reflecting persistent distribution pressure.
- Margin Compression and Integration Risks: Operating margin declined sequentially from 14.68% in Q3 2025 to 13.66% in Q4 2025 to 11.52% in Q1 2026, and gross margin slipped from 44.93% to 43.61%. The retail-heavy mix from Mattress Firm structurally dilutes margins, and no segment breakdown is available to isolate organic growth.
- High EV/EBITDA Relative to Peers: The EV/EBITDA of 25.49x is well above the 8–12x range typical for mature furnishings manufacturers, implying the market is pricing in significant EBITDA recovery. If synergy realization stalls, the multiple could compress sharply, pressuring the stock.
SGI Technical Analysis
Somnigroup is in a sustained downtrend that has been partially arrested by a recent stabilization attempt. The stock is down 22.45% over the past year and 24.77% year-to-date, a stark underperformance versus the S&P 500's +16.22% 1-year and +12.08% YTD returns, producing a relative strength of -38.67 over 12 months. At $66.76, the stock sits at just 16.8% of its 52-week range (low of $60.39, high of $98.56), meaning it is trading in the bottom quintile of its annual range — a positioning that historically signals either deep value or persistent distribution pressure, and given the magnitude of underperformance, the burden of proof remains on the bulls to demonstrate a durable trend reversal. The maximum drawdown of -37.25% underscores the severity of the de-rating from cycle highs.
Short-term momentum has diverged constructively from the longer-term trend. The stock is up 3.91% over the past month versus the S&P 500's -1.06%, generating a relative strength of +4.97 — the first meaningful positive divergence in the dataset. However, the 3-month change of -7.60% and 6-month change of -13.23% confirm that the intermediate trend remains negative, and the 1-month bounce appears to be a counter-trend rally within a larger downtrend rather than a confirmed reversal. The recent price action shows a rally from the $62.48 low on August 27 to $69.87 by September 4, followed by a pullback to $66.76, suggesting the bounce is losing steam near the $70 psychological resistance. Volume of approximately 2.15 million shares and a short ratio of 4.32 days indicate elevated short interest that could fuel squeezes on positive catalysts but also reflects persistent bearish conviction.
Key technical levels are well-defined. Support rests at the 52-week low of $60.39, with secondary support around the $62.50 area that held in late August; a breakdown below $60 would signal a resumption of the primary downtrend and likely target new lows. Resistance is layered at $70 (recent rally high), then $75-$78 (the June-July consolidation zone), with the 52-week high of $98.56 representing the full recovery target. The beta of 1.189 means the stock is approximately 19% more volatile than the market, which amplifies both the upside and downside of any breakout or breakdown — position sizing should account for this elevated volatility, particularly given the stock's tendency toward sharp directional moves as evidenced by the -37.25% max drawdown.
Beta
1.19
1.19x market volatility
Max Drawdown
-37.3%
Largest decline past year
52-Week Range
$60-$99
Price range past year
Annual Return
-26.3%
Cumulative gain past year
| Period | SGI Return | S&P 500 |
|---|---|---|
| 1m | -4.0% | -1.0% |
| 3m | -15.6% | +2.0% |
| 6m | -11.8% | +17.4% |
| 1y | -26.3% | +15.0% |
| ytd | -28.6% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SGI Fundamental Analysis
Somnigroup's revenue trajectory has inflected sharply higher, driven primarily by the Mattress Firm acquisition rather than organic momentum. Q1 2026 revenue of $1.802 billion grew 12.26% year-over-year versus Q1 2025's $1.605 billion, but the more telling comparison is the sequential progression: revenue has climbed from $1.605 billion in Q1 2025 to $1.881 billion in Q2 2025, $2.123 billion in Q3 2025, $1.868 billion in Q4 2025, and $1.802 billion in Q1 2026. The Q3 2025 peak reflects seasonal strength, but the year-over-year growth in Q1 2026 confirms the combined entity is generating materially higher revenue than the pre-acquisition baseline. The key question is whether this growth is sustainable or merely reflects the consolidation of Mattress Firm's retail revenue, as no segment breakdown is available to isolate organic versus acquired growth.
Profitability has improved markedly from the acquisition-related trough. Q1 2026 net income of $104.2 million compares favorably to the Q1 2025 loss of -$33.1 million, and the net margin has recovered to 5.78% from -2.06% a year earlier. Gross margin stands at 43.61% in Q1 2026, down slightly from 44.93% in Q4 2025 and 44.89% in Q3 2025, but up substantially from the depressed 36.17% in Q1 2025 when acquisition accounting and integration costs weighed on results. Operating margin of 11.52% in Q1 2026 is below the 13.66% in Q4 2025 and 14.68% in Q3 2025, suggesting some sequential compression, but the trailing operating margin of 13.18% and net margin of 5.14% indicate a business that is solidly profitable at scale. The gross margin in the low-to-mid 40s is consistent with premium branded consumer durables, though the retail mix from Mattress Firm structurally dilutes margins relative to a pure wholesale model.
Balance sheet leverage remains the central fundamental risk. Debt-to-equity of 2.66x is elevated, and the current ratio of 0.83 indicates current liabilities exceed current assets, a liquidity profile that demands consistent cash generation. Free cash flow on a trailing twelve-month basis is $736.8 million, which against a market cap of $18.39 billion yields an FCF yield of approximately 4.0% — reasonable but not compelling for a leveraged consumer discretionary name. Q1 2026 operating cash flow of $246.5 million and free cash flow of $186.0 million demonstrate the business can fund its $60.5 million quarterly capex, $36.7 million dividend, and $141.8 million debt repayment from internal cash flow, but the margin for error is thin. ROE of 12.36% and ROA of 5.53% are respectable but reflect the leverage effect; the cash flow to debt ratio of just 0.038 highlights that debt reduction will be a multi-year endeavor, leaving the company sensitive to interest rate and consumer demand shocks.
Quarterly Revenue
$1.8B
2026-03
Revenue YoY Growth
+12.3%
YoY Comparison
Gross Margin
43.6%
Latest Quarter
Free Cash Flow
$736800000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SGI Overvalued?
Because Somnigroup is profitable with trailing net income of $104.2 million in the most recent quarter and positive EPS of $0.02 on a trailing basis, the PE ratio is the appropriate primary metric. The trailing PE of 48x is optically rich, but the forward PE of 16.92x tells a dramatically different story — the gap implies the market expects earnings to more than double, consistent with analyst EPS estimates of $6.30 for the forward year versus the trailing $0.02. This enormous trailing-to-forward compression reflects the fact that trailing earnings are depressed by acquisition integration costs and interest expense, while forward estimates assume full synergy realization and normalized operations. The PEG ratio of -3.03 is not meaningful given the distorted trailing earnings base.
On a peer-relative basis, the valuation picture is mixed. The price-to-sales ratio of 2.46x and EV/Sales of 2.65x are moderate for a branded consumer durables company, but the price-to-book of 5.92x is elevated relative to the sector, reflecting the goodwill and intangible assets from the Mattress Firm deal rather than tangible book value creation. The EV/EBITDA of 25.49x is high for the furnishings and fixtures industry, where mature manufacturers typically trade in the 8-12x range, suggesting the market is pricing in significant EBITDA recovery. The forward PE of 16.92x, however, is below the broader consumer discretionary sector average, implying that on normalized earnings the stock is not expensive — the premium/discount debate hinges entirely on whether the $6.30 EPS estimate is achievable.
Historical context is instructive. The stock's PE ratio has ranged from 18.2x in Q3 2024 to 48x currently, with the current trailing multiple at the high end of its own historical band — but this is an artifact of depressed trailing earnings rather than multiple expansion. The PS ratio of 2.46x is actually near the low end of its historical range, which has spanned from 5.84x to 10.03x over the past three years, indicating that relative to sales, the stock is trading at a substantial discount to its own history. This divergence between elevated PE and depressed PS suggests the market is skeptical of margin recovery — if margins normalize toward historical levels, the PS multiple would re-rate higher, but if margin recovery stalls, the PE remains vulnerable.
PE
48.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 16x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.5x
Enterprise Value Multiple
Investment Risk Disclosure
Somnigroup's financial risk profile is dominated by its elevated leverage and tight liquidity. Debt-to-equity of 2.66x and a current ratio of 0.83 mean current liabilities exceed current assets, leaving little cushion for operational missteps. The cash flow to debt ratio of 0.038 indicates that even with $736.8 million in trailing free cash flow, reducing the debt burden will take years, and interest expense of $60 million per quarter consumes a significant portion of operating income ($207.6 million in Q1 2026). Additionally, the retail-heavy model from Mattress Firm structurally dilutes gross margins, which have declined sequentially from 44.93% in Q4 2025 to 43.61% in Q1 2026, and any further compression could impair the company's ability to service its debt.
Market and competitive risks are amplified by the stock's high beta of 1.189 and its exposure to discretionary consumer spending. The EV/EBITDA of 25.49x is well above the 8–12x typical for furnishings manufacturers, leaving the stock vulnerable to multiple compression if EBITDA recovery disappoints. The company faces intense competition from direct-to-consumer brands and other mattress retailers, and its integration of Mattress Firm may alienate other wholesale customers. Furthermore, the soft housing market and big-ticket consumer environment pose a persistent threat; the stock's 22.45% one-year decline and -38.67 relative strength versus the S&P 500 reflect these headwinds. Recent news of a dividend announcement is positive but does little to offset the broader macro sensitivity.
In a worst-case scenario, a consumer recession combined with integration missteps could trigger a sharp de-rating. If revenue growth stalls and margins compress further, the forward EPS estimate of $6.30 could be revised down, causing the stock to retest its 52-week low of $60.39, which represents a 9.5% decline from the current price of $66.76. A more severe scenario, such as a liquidity crunch or covenant breach, could push the stock toward the analyst low target of $66.00, essentially flat, but given the max drawdown of -37.25%, a decline to the $50s is not implausible if fundamentals deteriorate. From the current price, investors could lose 25–35% in a bear case, with the 52-week low serving as the first major support level.
FAQ
The most severe risk is financial: debt-to-equity of 2.66x and a current ratio of 0.83 leave little room for error, and interest expense of $60 million per quarter consumes a large share of operating income. Competitive risks include pressure from direct-to-consumer mattress brands and the potential alienation of wholesale customers due to Mattress Firm's retail expansion. Macroeconomic risks are significant given the beta of 1.189 and exposure to discretionary consumer spending, which is sensitive to housing market weakness and high interest rates. Company-specific risks include integration challenges from the Mattress Firm acquisition, which have already contributed to margin compression and a 24.77% YTD stock decline.
Our 12-month forecast assigns a 50% probability to a base case with a target range of $75–$91.89, assuming gradual margin recovery and steady deleveraging. The bull case (30% probability) targets $91.89–$105.00 if integration synergies exceed expectations and EPS hits $6.30. The bear case (20% probability) targets $60.39–$66.00 if consumer demand weakens or margin recovery stalls. The most likely scenario is the base case, hinging on the company achieving high-single-digit revenue growth and stabilizing operating margins around 12–13%. Key catalysts include upcoming earnings reports and any updates on debt reduction.
SGI appears undervalued on a forward basis, with a forward PE of 16.92x and a PS ratio of 2.46x, which is near the low end of its historical range of 5.84x–10.03x. However, the trailing PE of 48x and EV/EBITDA of 25.49x suggest the market is pricing in a significant earnings recovery that has yet to fully materialize. Relative to peers in the furnishings industry, the EV/EBITDA is elevated, but the forward PE is below the consumer discretionary sector average. The valuation implies the market expects EPS to more than double to $6.30, and if that target is met, the stock is cheap; if not, it could be overvalued.
SGI could be a good buy for risk-tolerant investors seeking value, given the 37.6% upside to the analyst average target of $91.89 and the forward PE of 16.92x, which is below the sector average. However, the stock carries significant risks, including a debt-to-equity of 2.66x and a current ratio of 0.83, which could strain liquidity in a downturn. The bear case downside to the 52-week low of $60.39 represents a 9.5% decline, but a more severe scenario could see 25–35% losses. For those with a long-term horizon and belief in the Mattress Firm integration, the risk/reward is favorable, but conservative investors should wait for clearer signs of margin recovery and deleveraging.
SGI is better suited for long-term investors with a horizon of at least 2–3 years, given the multi-year nature of the Mattress Firm integration and deleveraging process. The stock's high beta (1.189) and wide target range make it too volatile for short-term trading, and the low dividend yield (0.69%) offers little income support. Earnings visibility is improving but remains uncertain, with the forward EPS estimate of $6.30 representing a significant recovery from trailing EPS of $0.02. A minimum holding period of 18–24 months is recommended to allow for synergy realization and potential multiple expansion.
